Antimicrobial resistance (AMR) constitutes a pressing and intensifying global health crisis, significantly exacerbated by the inappropriate utilization and excessive application of antibiotics in livestock agriculture. The excessive use of antibiotics, including prophylactic and metaphylactic administration as well as growth-promotion applications, exacerbates selective pressures, fostering the proliferation of multidrug-resistant (MDR) bacterial strains. Pathogens such as Escherichia coli, Salmonella spp., and Staphylococcus aureus can be transmitted to humans through direct contact, contaminated food, and environmental pathways, establishing a clear link between livestock farming and human AMR outbreaks. These challenges are particularly pronounced in regions with limited veterinary oversight and weak regulatory frameworks. Addressing these issues requires the implementation of sustainable practices, enhanced antibiotic stewardship, and strengthened interdisciplinary collaboration. This review underscores the critical need for a One Health approach to mitigate AMR, recognizing the interconnectedness of human, animal, and environmental health in safeguarding global public health.

This comprehensive review elucidates the profound relationship between the human microbiome and breast cancer management. Recent findings highlight the significance of microbial alterations in tissue, such as the gut and the breast, and their role in influencing the breast cancer risk, development, progression, and treatment outcomes. We delve into how the gut microbiome can modulate systemic inflammatory responses and estrogen levels, thereby impacting cancer initiation and therapeutic drug efficacy. Furthermore, we explore the unique microbial diversity within breast tissue, indicating potential imbalances brought about by cancer and highlighting specific microbes as promising therapeutic targets. Emphasizing a holistic One Health approach, this review underscores the importance of integrating insights from human, animal, and environmental health to gain a deeper understanding of the complex microbe–cancer interplay. As the field advances, the strategic manipulation of the microbiome and its metabolites presents innovative prospects for the enhancement of cancer diagnostics and therapeutics. However, rigorous clinical trials remain essential to confirm the potential of microbiota-based interventions in breast cancer management.

Today, over 300 million individuals worldwide are afflicted by severe fungal infections, many of whom will perish. Fungi, as a result of their plastic genomes have the ability to adapt to new environments and extreme conditions as a consequence of globalization, including urbanization, agricultural intensification, and, notably, climate change. Soils and the impact of these anthropogenic environmental factors can be the source of pathogenic and non-pathogenic fungi and subsequent fungal threats to public health. This underscores the growing understanding that not only is fungal diversity in the soil mycobiome a critical component of a functioning ecosystem, but also that soil microbial communities can significantly contribute to plant, animal, and human health, as underscored by the One Health concept. Collectively, this stresses the importance of investigating the soil microbiome in order to gain a deeper understanding of soil fungal ecology and its interplay with the rhizosphere microbiome, which carries significant implications for human health, animal health and environmental health.

Klebsiella pneumoniae carbapenemases (KPCs) are a group of class A β-lactamases of Gram-negative bacteria leading to difficult-to-treat infections. We evaluated the global epidemiology of KPC-producing Gram-negative clinical isolates. A systematic search of six databases (Cochrane Library, Embase, Google Scholar, PubMed, Scopus, and Web of Science) was conducted. Extracted data were tabulated and evaluated. After screening 1993 articles, 119 were included in the study. The included studies originated from Asia (n = 49), Europe (n = 29), North America (n = 14), South America (n = 11), and Africa (n = 3); 13 studies were multicontinental. The most commonly reported KPC-producing species were Klebsiella pneumoniae (96 studies) and Escherichia coli (52 studies), followed by Enterobacter cloacae (31), Citrobacter spp. (24), Klebsiella oxytoca (23), Serratia spp. (15), Enterobacter spp. (15), Acinetobacter baumannii complex (13), Providencia spp. (11), Morganella spp. (11), Klebsiella aerogenes (9), Pseudomonas aeruginosa (8), Raoultella spp. (8), Proteus spp. (8), and Enterobacter aerogenes (6). Among the studies with specific bla_KPC gene detection, 52/57 (91%) reported the isolation of bla_KPC-2 and 26/57 (46%) reported bla_KPC-3. The antimicrobial resistance of the studied KPC-producing isolates was the lowest for ceftazidime–avibactam (0–4%). Resistance to polymyxins, tigecycline, and trimethoprim–sulfamethoxazole in the evaluated studies was 4–80%, 0–73%, and 5.6–100%, respectively. Conclusions: The findings presented in this work indicate that KPC-producing Gram-negative bacteria have spread globally across all continents. Implementing proper infection control measures, antimicrobial stewardship programs, and enhanced surveillance is crucial.

Introduction: Eravacycline is a new fluorocycline antibiotic with a broad spectrum of antimicrobial activity approved for the treatment of patients with complicated intra-abdominal infections. This systematic review aimed to evaluate the published data on the resistance of Gram-negative bacterial isolates to eravacycline. Methods: We identified relevant publications by systematically searching Embase, PubMed, Scopus, and Web of Science from their inception to 29 August 2025. Published antimicrobial resistance breakpoints of the European Committee on Antimicrobial Susceptibility Testing (EUCAST) and the US Food and Drug Administration (FDA) were used. Results: Data on 59,922 Gram-negative bacterial clinical isolates were retrieved from 68 articles after the screening of 283 potentially relevant studies. The resistance of consecutive (non-selected) Escherichia coli ranged from 0.9% to 9.6%. The MIC₅₀ values of eravacycline were ≤0.5 mg/L for Acinetobacter baumannii isolates, including carbapenem-resistant A. baumannii, in the majority of studies. The proportions of resistance were higher among other lactose non-fermenting Gram-negative bacterial isolates, especially Pseudomonas aeruginosa, as well as among selected E. coli with advanced patterns of antimicrobial resistance. Conclusions: The evaluated data support the adequate antimicrobial activity of eravacycline against most Gram-negative bacterial clinical isolates. However, in vitro antimicrobial susceptibility testing and modern molecular diagnostic tests, including those that examine mechanisms of resistance, are helpful for the appropriate use of eravacycline in clinical practice.

Background: Current evidence suggests that more than half of all antimicrobials are used in the sector of food-producing animals, thus constituting a major risk factor for development and spread of antimicrobial resistance (AMR). Methods: This cross-sectional study assessed the knowledge, attitudes, and practices regarding antimicrobial resistance (AMR) and antimicrobial use (AMU) among veterinarians (n = 26) working with food-producing animals and operators (n = 165) of establishments that keep food-producing animals, across all districts of Cyprus between October and December 2024. Results: Most veterinarians demonstrated sufficient knowledge regarding AMR and AMU; however, certain knowledge gaps were identified. There was a general trend toward desired responses aimed at reducing AMU. Despite this, the level of responses advocating for restrictions on the use of specific priority antimicrobials and broad-spectrum antibacterials was unsatisfactory. Over half of veterinarians prescribed Category B substances. Furthermore, there was no significant association between the use of “restricted” antibiotics and veterinarians’ level of knowledge nor between antibiotic use and the practice of microbiological culture and susceptibility testing. Among operators, positive attitudes were significant predictors of implementing of good practices. Additionally, operators who had contracts with a veterinarians were more likely to follow good practices. Conclusions: There is a need for further education on AMR in the veterinary sector in the Republic of Cyprus. Raising awareness among animal producers, is also crucial, along with enforcing a policy on antimicrobial use. Comprehensive governance involving all stakeholders must be implemented to address AMR more effectively.